2nd GLP-1-Based Therapeutics Summit

If you thought that 2024 was the year for GLP-1 Agonists, then hold on for 2025!

The booming success of Semaglutide and Tirzepatide continues to shake up the pharmaceutical landscape worldwide, with some claiming that GLP-1s are poised to reshape the entire economy.

We have seen first-in-class GLP-1s from Eli Lilly & Co. and Novo Nordisk, but the race is on to develop the best-in-class GLP-1 with improved muscle retention, reduced side effects, and patient-friendly formulations. Not to mention the indication expansion into MASH, sleep apnea, addiction, and neurodegenerative diseases.

The 2nd GLP-1-Based Therapeutics Summit returns to tackle the challenges in best-in-class GLP-1 development and indication expansion with new clinical data, new preclinical data, and 18+ expert speakers including Eli Lily, Regeneron, Roche, Novo Nordisk, Fractyl Health and more at the forefront of the field.

Where: Wyndham Boston Beacon Hill

When: April 29 - May 1

Program: https://ter.li/beknr5

This summit is your dedicated platform for leaders and decision-makers to connect, collaborate, and continue to transform healthcare as we know it through the development of GLP-1s.

View the full agenda and speakers here: https://ter.li/beknr5